Treatment of attention deficits in neurological disorders
- 1 December 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 19 (6) , 613-618
- https://doi.org/10.1097/01.wco.0000247605.57567.9a
Abstract
Recent work has revealed the impact of deficits of attention on patients with neurological disorders. Here we discuss therapeutic interventions that have been used across a range of conditions, highlighting common themes both in the nature of the attention deficits and the strategies employed to treat them. Cholinesterase inhibitors improve attention, as well as memory, in several conditions including cortical Lewy body disease, Parkinson's disease dementia, traumatic brain injury and Alzheimer's disease. Recent studies suggest that cholinergic stimulation may boost attention further if more specific nicotinic cholinergic agonists are used, or if cholinesterase inhibitors are combined with other agents. Monoaminergic drugs have been shown to improve attention in traumatic brain injury, attention-deficit hyperactivity disorder and hemispatial neglect following right-hemisphere stroke. New compounds targeting other neurotransmitter systems are currently being tested, while several types of behavioural intervention have shown promise, particularly in stroke patients. Pharmacological and behavioural interventions can improve attention in neurological patients. In the future, optimum therapy may depend on careful delineation of the components of attention that are impaired as well as assessment of the potential for surviving brain regions to compensate for attention deficits.Keywords
This publication has 47 references indexed in Scilit:
- Benefits of rivastigmine on attention in dementia associated with Parkinson diseaseNeurology, 2005
- The role of levodopa in the management of dementia with Lewy bodiesJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Rivastigmine for Dementia Associated with Parkinson's DiseaseNew England Journal of Medicine, 2004
- Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy BodiesDementia and Geriatric Cognitive Disorders, 2004
- Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patientsEuropean Journal of Neurology, 2004
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2004
- The Subtype-Selective Nicotinic Acetylcholine Receptor Agonist SIB-1553A Improves Both Attention and Memory Components of a Spatial Working Memory Task in Chronic Low Dose 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated MonkeysThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international studyThe Lancet, 2000
- Attention and executive deficits in Alzheimer's disease: A critical reviewBrain, 1999
- Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacologyProgress in Neurobiology, 1998